RT Journal Article
SR Electronic
T1 Non-invasive multi-cancer detection using DNA hypomethylation of LINE-1 retrotransposons
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.01.20.23288905
DO 10.1101/2024.01.20.23288905
A1 Michel, Marc
A1 Heidary, Maryam
A1 Mechri, Anissa
A1 Da Silva, Kévin
A1 Gorse, Marine
A1 Dixon, Victoria
A1 von Grafenstein, Klaus
A1 Bianchi, Charline
A1 Hego, Caroline
A1 Rampanou, Aurore
A1 Lamy, Constance
A1 Kamal, Maud
A1 Le Tourneau, Christophe
A1 Séné, Mathieu
A1 Bièche, Ivan
A1 Reyes, Cecile
A1 Gentien, David
A1 Stern, Marc-Henri
A1 Lantz, Olivier
A1 Cabel, Luc
A1 Pierga, Jean-Yves
A1 Bidard, François-Clément
A1 Azencott, Chloé-Agathe
A1 Proudhon, Charlotte
YR 2024
UL http://medrxiv.org/content/early/2024/10/30/2024.01.20.23288905.abstract
AB Purpose The detection of circulating tumor DNA, which allows non-invasive tumor molecular profiling and disease follow-up, promises optimal and individualized management of patients with cancer. However, detecting small fractions of tumor DNA released when the tumor burden is reduced remains a challenge.Experimental Design We implemented a new highly sensitive strategy to detect base-pair resolution methylation patterns from plasma DNA and assessed the potential of hypomethylation of LINE-1 retrotransposons as a non-invasive multi-cancer detection biomarker. The DIAMOND (Detection of Long Interspersed Nuclear Element Altered Methylation ON plasma DNA) method targets 30-40,000 young L1 scattered throughout the genome, covering about 100,000 CpG sites and is based on a reference-free analysis pipeline.Results Resulting machine learning-based classifiers showed powerful correct classification rates discriminating healthy and tumor plasmas from 6 types of cancers (colorectal, breast, lung, ovarian, gastric cancers and uveal melanoma including localized stages) in two independent cohorts (AUC = 88% to 100%, N = 747). DIAMOND can also be used to perform copy number alterations (CNA) analysis which improves cancer detection.Conclusions This should lead to the development of more efficient non-invasive diagnostic tests adapted to all cancer patients, based on the universality of these factors.Statement of significance The DIAMOND assay is a new highly sensitive strategy to detect base-pair resolution methylation patterns of LINE-1 retrotransposons (L1) from plasma DNA. It targets 30-40,000 young L1 scattered throughout the genome, covering about 100,000 CpG sites and is based on a reference-free analysis pipeline. This provided high coverage data using affordable sequencing depth, which is instrumental to achieve high sensitivity and work with minute amounts of cell-free DNA. Resulting machine learning-based classifiers showed powerful discrimination between healthy and tumor plasmas from 6 types of cancers (colorectal, breast, lung, ovarian, gastric cancers and uveal melanoma including localized stages) in two independent cohorts (AUC = 88% to 100%, N = 747). DIAMOND data can also be used to perform copy number alterations (CNA) analysis which improves cancer detection.Competing Interest StatementCP, MM, MH, and CAA have an ongoing patent application relating to circulating tumor DNA analysis.Funding StatementThe NGS facility was supported by ANR-10-EQPX-03 (Equipex) and ANR-10-INBS-09-08 (France Genomique Consortium) grants and by the Canceropole Ile-de-France. This research was supported by grants, of which C.P. was recipient, from: The European Research Council (ERC-StG EpiDetect), The Ligue contre le cancer (RS17-75-75), The prematuration program of the Centre National pour la Recherche Scientifique (CNRS), The SiRIC 2 Curie program (INCa-DGOS-Inserm_12554) The DEEP Strive funding (LABEX DEEP 11-LBX0044). CAA research was supported in part by the French government under management of Agence Nationale de la Recherche as part of the Investissements d avenir program, reference ANR-19-P3IA-0001 (PRAIRIE 3IA Institute).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Healthy white blood cells and healthy plasma were collected from blood of healthy donors through the French blood establishment (agreement #16/EFS/031) under French and European ethical practices. Blood samples from patients treated at the Institut Curie (Paris, France) were collected, after written informed consent, as part of the following studies: resectable metastatic colorectal cancers from the Prodige14 trial (approved by a French Personal Protection Committee: 'Comite de Protection des Personnes' (CPP) and registered in ClinicalTrials.gov under NCT01442935); non-small cell lung cancer and metastatic HR+ HER2-breast cancer from the ALCINA study (approved by a French Personal Protection Committee and registered in ClinicalTrials.gov under NCT02866149; treatment-naive ovarian cancer or triple-negative breast cancer patients eligible for surgery or neoadjuvant chemotherapy from the SCANDARE study (approved by the French National Agency for the Safety of Medicines and Health Products: 'Agence National de Securite du Medicament' (ANSM), a French Personal Protection Committee and registered in ClinicalTrials.gov under NCT03017573); multiple-types of metastatic cancers from the SHIVA02 study (approved by the French National Agency for the Safety of Medicines and Health Products: 'Agence National de Securite du Medicament' (ANSM), a French Personal Protection Committee and registered in ClinicalTrials.gov under NCT03084757), non-metastatic operable gastric cancers and advanced uveal melanoma from CTC-CEC-ADN study (approved by a French Personal Protection Committee and registered in ClinicalTrials.gov under NCT02220556). Additional archived samples were also retrieved from the biobank of the Institut Curie, patients having provided informed consent for research use. All samples were obtained in accordance with the ethical guidelines, with the principles of Good Clinical Practice and the Declaration of Helsinki. This study was approved by the Internal Review Board and Clinical Research Committee of the Institut Curie.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesData have been deposited as methylation matrices (CG% or haplotypes%) on the Zenodo database with the following accession code: https://zenodo.org/uploads/12206227 and as compressed FASTQ files at the European Genome-Phenome Archive at https://ega-archive.org/ under the accession code EGAD50000000646. WGBS sequencing data were downloaded from publicly available database at https://zenodo.org/records/7779198 and from the National Center for Biotechnology Information (https://www.ncbi.nlm.nih.gov) under the accession number PRJNA494975. The code used to analyze the data is available on github: https://github.com/ProudhonLab.